News
 
Pharmaceuticals Newsletter - May 21 to May 25, 2012
India Infoline News Service/19:38,May 25, 2012
Piramal Healthcare Limited announced today that Phase I clinical trial data for its investigational new drug candidate P1446A-05 will be presented at the Annual Meeting of the American Society for Clinical Oncology (ASCO) being convened in Chicago from June 1-5, 2012.
list India Infoline Weekly Newsletter - May 25, 2012
list Pfizer recalls Advil bottles from distributor centers
list Teva outlines financial estimates for 2012
list Ranbaxy hires advisers for resolving consent decree with USFDA

Calendar

May-2012
M T W T F S S
21 22 23 24 25 26 27
Economic Events
list Corporate Service Price (YoY)
list Hometrack Housing Survey (MoM)
Results
list No result today
IPO
listNo IPO today
 

Dr. Reddy laboratories gets UK MHRA nod for Risedronate Sodium

Capital Market / 09:46 , Mar 30, 2011

value of branded formulation sale is about US$ 221 million

The UK Medicines and Healthcare products Regulatory Agency (UK MHRA) has granted Dr. Reddy laboratories(UK) Ltd, a subsidiary of Dr. Reddy laboratories got marketing authorization for the Risedronate Sodium 5 mg and 35 mg tablets.

It was originally developed and marketed by the Warner Chilcott under the brand name drug Actonel. It is indicative for the treatment of postmenopausal osteoporosis. According to Warner Chilcott annual report Actonel has annual sales of US$ 221 million for the 12 months ended December 2009.

For the US Market, Teva Pharmaceuticals already received the final approval for the Abbreviated New Drug Application(ANDA) from the US Food and Drug Administration (FDA).

 



Rate This Article Rate 1 Rate 2 Rate 3 Rate 4 Rate 5